Sanofi Sees China Growth Bolstered By County Hospitals Push
This article was originally published in PharmAsia News
Executive Summary
Thousands of county hospitals offer significant growth opportunities for the next 10 years, says Sanofi SVP Jean-Luc Lowinski, but adds the challenges at building the market are unique for multinational drug manufacturers in China.
You may also be interested in...
Pfizer Teams With Distributor Jointown To Delve Deeper Into China's Rural Markets
SHANGHAI - Pfizer Inc., like many of its Big Pharma peers is seeking out local Chinese partners to gain access to China's lower-tier cities and rural areas. To that end, the world's largest pharma company recently signed an agreement with China's third-largest pharma distributor Jointown Pharmaceutical Group Co., Ltd. to distribute Pfizer products in markets outside of big cities
With Latest Round Of Cuts, China Continues March To Narrow Gap Between Big Pharma And Local Generics
SHANGHAI - As expected, China's powerful National Development and Reform Commission announced Aug. 5 a new round of price cuts, this time targeting hormone and endocrinology drugs and central nervous system drugs, with an average cut of roughly 14%, according to analysts
CEO Podcast: Hengrui's US Subsidiary's CEO, CMO On Chinese Pharma Going Global
While many pharma firms in China choose to partner with US companies, Jiangsu Hengrui is relying on itself to go global. The Chinese pharma giant is betting on its newly established US subsidiary Luzsana in a major move to make its wide-ranging products more available, accessible and affordable to patients in the US and the rest of the world.